{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:01:28Z","timestamp":1785232888050,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.resinv.2021.04.005","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:17:51Z","timestamp":1620947871000},"page":"819-826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2830-755X","authenticated-orcid":false,"given":"Shu","family":"Hisata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6213-3584","authenticated-orcid":false,"given":"Sakae","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6384-5022","authenticated-orcid":false,"given":"Shinyu","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kizuku","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9630-8066","authenticated-orcid":false,"given":"Yoshinobu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7120-8517","authenticated-orcid":false,"given":"Yuko","family":"Waseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2384-601X","authenticated-orcid":false,"given":"Yoshinori","family":"Tanino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yatera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seishu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Inase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2021.04.005_bib1","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2021.04.005_bib2","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2021.04.005_bib3","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2021.04.005_bib4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2021.04.005_bib5","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2021.04.005_bib6","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1183\/09031936.00198013","article-title":"Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis","volume":"45","author":"Ogura","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.04.005_bib7","doi-asserted-by":"crossref","first-page":"1801060","DOI":"10.1183\/13993003.01060-2018","article-title":"No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone","volume":"53","author":"Richeldi","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.04.005_bib8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201706-1301OC","article-title":"Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial","volume":"197","author":"Vancheri","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2021.04.005_bib9","doi-asserted-by":"crossref","first-page":"1800230","DOI":"10.1183\/13993003.00230-2018","article-title":"Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis","volume":"52","author":"Flaherty","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.04.005_bib10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.resinv.2018.03.003","article-title":"Japanese guideline for the treatment of idiopathic pulmonary fibrosis","volume":"56","author":"Homma","year":"2018","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2021.04.005_bib11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies","volume":"279","author":"J Lazarou","year":"1998","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.resinv.2021.04.005_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12931-020-1315-4","article-title":"Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry","volume":"21","author":"Holtze","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2021.04.005_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2021.04.005_bib14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.resinv.2015.06.001","article-title":"All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis","volume":"53","author":"Ogura","year":"2015","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2021.04.005_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236935","article-title":"Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity <\/= 50%: a multi-center retrospective analysis","volume":"15","author":"Senoo","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.resinv.2021.04.005_bib16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.rmed.2013.06.011","article-title":"Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice","volume":"107","author":"Okuda","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2021.04.005_bib17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.resinv.2013.09.002","article-title":"Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis","volume":"52","author":"Arai","year":"2014","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2021.04.005_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000363064","article-title":"Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases","volume":"88","author":"Oltmanns","year":"2014","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2021.04.005_bib19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.rmed.2013.11.005","article-title":"Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis","volume":"108","author":"Chaudhuri","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2021.04.005_bib20","doi-asserted-by":"crossref","first-page":"32608","DOI":"10.3402\/ecrj.v3.32608","article-title":"Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results","volume":"3","author":"Salih","year":"2016","journal-title":"Eur Clin Respir J"},{"key":"10.1016\/j.resinv.2021.04.005_bib21","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/resp.13024","article-title":"Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions","volume":"22","author":"Galli","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2021.04.005_bib22","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3389\/fphar.2018.01480","article-title":"South-west of england's experience of the safety and tolerability pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)","volume":"9","author":"Barratt","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.resinv.2021.04.005_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12890-018-0736-z","article-title":"Pirfenidone improves survival in IPF: results from a real-life study","volume":"18","author":"Margaritopoulos","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2021.04.005_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00084-2018","article-title":"Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study","volume":"4","author":"Cottin","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2021.04.005_bib25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000448288","article-title":"Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis","volume":"92","author":"Bonella","year":"2016","journal-title":"Respiration"},{"key":"10.1016\/j.resinv.2021.04.005_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40169-017-0172-3","article-title":"Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres","volume":"6","author":"Toellner","year":"2017","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.resinv.2021.04.005_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00172-2019","article-title":"Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study","volume":"6","author":"Antoniou","year":"2020","journal-title":"ERJ Open Res"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534521000757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534521000757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:31:54Z","timestamp":1761949914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534521000757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2212534521000757"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2021.04.005","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2021.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}